Comprehensive molecular characterization of gastric adenocarcinoma
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical characteristics has been complicated by histological and aetiological heterogeneity. Here we describe a comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project. We propose a molecular classification dividing gastric cancer into four subtypes: tumours positive for Epstein–Barr virus, which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2); microsatellite unstable tumours, which show elevated mutation rates, including mutations of genes encoding targetable oncogenic signalling proteins; genomically stable tumours, which are enriched for the diffuse histological variant and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins; and tumours with chromosomal instability, which show marked aneuploidy and focal amplification of receptor tyrosine kinases. Identification of these subtypes provides a roadmap for patient stratification and trials of targeted therapies. The Cancer Genome Atlas reports on molecular evaluation of 295 primary gastric adenocarcinomas and proposes a new classification of gastric cancers into 4 subtypes, which should help with clinical assessment and trials of targeted therapies. This contribution from The Cancer Genome Atlas (TCGA) project describes the molecular evaluation of 295 primary gastric adenocarcinomas. Based on the results, the authors propose a novel classification separating gastric cancers into four subtypes according to: Epstein–Barr virus positive status, microsatellite instability, chromosomal instability or genomic stability. Given the histologic and etiologic heterogeneity of gastric cancer identification of these subtypes, using a schema that can readily be applied to patient samples should help with patient stratification and trials of targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many of the miRNAs were also reported by a recent systems biology paper from TCGA in 2014 [34].”
From Bioinformatic Interrogation of 5p-arm and 3p-arm Specific miRNA Expression Using TCGA Datasets (2015) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“The TP53/APC double knockout (DKO) organoid line was established in our previous studies by sequentially disrupting TP53 and APC37, two common oncogenic loci in gastric adenocarcinoma38,39, from non-neoplastic human gastric organoids (Fig. S1A).”
From Large-scale CRISPR screening in primary human 3D gastric organoids enables comprehensive dissection of gene-drug interactions (2025) · cites this paper as [38]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Fusobacterium spp. is important in the development and progression of gastrointestinal tumors1,19,34,35”
From RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach (2020) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Self-citationLAURÉN, P. (1965) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/apm.1965.64.1.31 · Cited by 6,133
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationWHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Cell Migration: Integrating Signals from Front to Back
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003) · Science · doi:10.1126/science.1092053 · Cited by 4,978
Helicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,465
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Research works printed but not linked: 2
- Ferlay, J. et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase 11, http://globocan.iarc.fr, accessed on January 15, 2014 (2013)
- The Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012) · DOI · Paper page
Cited by
Items 601–700 of 1,024
Zheng, X., Wang, R., Zhang, X., Sun, Y., Zhang, H., Zhao, Z., Zheng, Y., Luo, J., Zhang, J., Wu, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30459-5 · Cited by 111
“The five self-confidence scales [1, 2, 3, 4, 5] were simply linearly transformed to the corresponding probabilities [0.”
MethodThe role of cancer-associated fibroblasts in tumorigenesis of gastric cancer
Sun, H., Wang, X., Wang, X., Xu, M., & Sheng, W. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05320-8 · Cited by 112
Molecular profile of bladder cancer progression to clinically aggressive subtypes
Guo, C. C., Lee, S., Lee, J. G., Chen, H., Zaleski, M. P., Choi, W., McConkey, D. J., Wei, P., & Czerniak, B. A. (2024) · Nature Reviews Urology · doi:10.1038/s41585-023-00847-7 · Cited by 111
“This subset of purely mesenchymal sarcomatoid carcinomas has overlapping features with the claudin-low and TCGA cluster IV subtypes identified previously 52,53 .”
Oue, N., Sentani, K., Sakamoto, N., & Yasui, W. (2015) · Cancer Science · doi:10.1111/cas.12706 · Cited by 99
Hierro, C., Rodon, J. A., & Tabernero, J. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.027 · Cited by 99
Wu, J., Zhai, J., Li, C.-Y., Tan, A., Wei, P., Shen, L., & He, M. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0631-0 · Cited by 103
Wang-Bishop, L., Chen, Z., Gomaa, A. R., Lockhart, A. C., Salaria, S. N., Wang, J., Lewis, K. B., Ecsedy, J., Washington, K. M., Beauchamp, R. D., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.10.030 · Cited by 95
Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments
Ham, I., Lee, D., & Hur, H. (2019) · Journal of Oncology · doi:10.1155/2019/6270784 · Cited by 108
Xiao, J., Lin, L., Luo, D., Shi, L., Chen, W., Fan, H., Li, Z., Ma, X., Ni, P., Yang, L., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0215-2 · Cited by 102
Bakkalci, D., Jia, Y., Winter, J. R., Lewis, J. E. A., Taylor, G. S., & Stagg, H. R. (2020) · Journal of Global Health · doi:10.7189/jogh.10.010405 · Cited by 94
Immunotherapy for Esophageal and Gastric Cancer
Kelly, R. J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175231 · Cited by 104
Viral oncogenesis in cancer: from mechanisms to therapeutics
Xiao, Q., Liu, Y., Li, T., Wang, C., He, S., Zhai, L., Yang, Z., Zhang, X., Wu, Y., & Liu, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02197-9 · Cited by 130
Regulatory mechanisms of PD-L1 expression in cancer cells
Shi, Y. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2226-9 · Cited by 92
Saju, P., Murata‐Kamiya, N., Hayashi, T., Senda, Y., Nagase, L., Noda, S., Matsusaka, K., Funata, S., Kunita, A., Urabe, M., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.26 · Cited by 99
Molecular Classification of Gastric Adenocarcinoma
Wang, Q., Liu, G., & Hu, C. (2019) · Gastroenterology Research · doi:10.14740/gr1187 · Cited by 123
Kwon, M., Kim, G., Kim, R., Kim, K., Kim, S. T., Smith, S. A., Mortimer, P. G. S., Hong, J. Y., Loembé, A., Irurzun‐Arana, I., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005041 · Cited by 104
Taïeb, J., Moehler, M. H., Boku, N., Ajani, J. A., Ruiz, E. Y., Ryu, M., Guenther, S., Chand, V. K., & Bang, Y. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.004 · Cited by 92
Sun, Q., Li, J., Li, F., Li, H., Bei, S., Zhang, X., & Feng, L. (2019) · Cell Proliferation · doi:10.1111/cpr.12687 · Cited by 90
The Crosstalk between Microbiome and Immune Response in Gastric Cancer
Nasr, R., Shamseddine, A. I., Mukherji, D., Nassar, F. J., & Temraz, S. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186586 · Cited by 99
SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation
Fahey, C. C., & Davis, I. J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026468 · Cited by 99
Liu, H., Shen, Z., Wang, Z., Wang, X., Zhang, H., Qin, J., Qin, X., Xu, J., & Sun, Y. (2016) · Scientific Reports · doi:10.1038/srep21319 · Cited by 97
DNA methylation biomarkers for head and neck squamous cell carcinoma
Zhou, C., Ye, M., Ni, S., Li, Q., Ye, D., Li, J., Shen, Z., & Deng, H. (2018) · Epigenetics · doi:10.1080/15592294.2018.1465790 · Cited by 92
Diffuse Gastric Cancer: A Summary of Analogous Contributing Factors for Its Molecular Pathogenicity
Ansari, S., Gantuya, B., Tuan, V. P., & Yamaoka, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082424 · Cited by 104
LncRNA UCA1 promotes tumor metastasis by inducing miR-203/ZEB2 axis in gastric cancer
Gong, P., Qiao, F., Wu, H., Cui, H., Li, Y., Zheng, Y., Zhou, M., & Fan, H. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1170-0 · Cited by 94
Notch and mTOR Signaling Pathways Promote Human Gastric Cancer Cell Proliferation
Hibdon, E. S., Razumilava, N., Keeley, T. M., Wong, G., Solanki, S. A., Shah, Y. M., & Samuelson, L. C. (2019) · Neoplasia · doi:10.1016/j.neo.2019.05.002 · Cited by 95
Cao, L., Zhu, S., Lu, H., Soutto, M., Bhat, N. S., Chen, Z., Peng, D., Lin, J., Lu, J. K., Li, P., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.01.046 · Cited by 97
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Wang, D., Lin, J., Yang, X., Long, J., Bai, Y., Yang, X., Mao, Y., Sang, X., Seery, S., & Zhao, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0730-9 · Cited by 90
Dai, W., Cheung, A. K. L., Ko, J. M. Y., Cheng, Y., Zheng, H., Ngan, R. K., Ng, W. T., Lee, A. W. M., Yau, C. C., Lee, V. H.-F., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.451 · Cited by 98
MicroRNA-7/NF-κB signaling regulatory feedback circuit regulates gastric carcinogenesis
Zhao, X.-D., Lu, Y.-Y., Guo, H., Xie, H.-H., He, L.-J., Shen, G.-F., Zhou, J.-F., Li, T., Hu, S.-J., Zhou, L., et al. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201501073 · Cited by 89
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives
Moehler, M. H., Delic, M., Goepfert, K., Aust, D. E., Grabsch, H. I., Halama, N., Heinrich, B., Julié, C., Lordick, F., Lutz, M. P., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.020 · Cited by 97
Frizzled7: A Promising Achilles’ Heel for Targeting the Wnt Receptor Complex to Treat Cancer
Phesse, T. J., Flanagan, D. J., & Vincan, E. (2016) · Cancers · doi:10.3390/cancers8050050 · Cited by 98
Exome-wide somatic mutation characterization of small bowel adenocarcinoma
Hänninen, U. A., Katainen, R., Tanskanen, T. J., Plaketti, R., Laine, R., Hamberg, J., Ristimaki, A. P., Pukkala, E., Taipale, M., Mecklin, J., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007200 · Cited by 90
Kim, J., Kim, B., Kang, S. Y., Heo, Y. J., Park, S. H., Kim, S. T., Kang, W. K., Lee, J., & Kim, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00314 · Cited by 98
CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
Harvey, J. B., Phan, L. H., Villarreal, O. E., & Bowser, J. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00508 · Cited by 92
Phase separation drives decision making in cell division
Liu, X., Liu, X., Wang, H., Dou, Z., Ruan, K., Hill, D. L., Li, L., Shi, Y., & Yao, X. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.011746 · Cited by 89
Huang, K. K., Huang, J., Wu, J., Lee, M., Tay, S. T., Kumar, V., Ramnarayanan, K., Padmanabhan, N., Xu, C., Tan, A. L. K., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02261-x · Cited by 95
Lee, S. H., Lee, D., Choi, J., Oh, H. J., Ham, I., Ryu, D., Lee, S.-Y., Han, D.-J., Kim, S., Moon, Y., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332901 · Cited by 120
Immunotherapy and patients treated for cancer with microsatellite instability
Colle, R., Cohen, R., Cochereau, D., Duval, A., Lascols, O., López‐Trabada, D., Afchain, P., Trouilloud, I., Parc, Y. R., Lefèvre, J. H., et al. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.11.006 · Cited by 102
Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives
Vedeld, H. M., Goel, A., & Lind, G. E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.004 · Cited by 92
Wang, Z., Dai, J., Hu, N., Miao, X., Abnet, C. C., Yang, M., Freedman, N. D., Chen, J., Burdette, L. A., Zhu, X., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-310612 · Cited by 101
Yoon, C., Cho, S., Chang, K. K., Park, D. J., Ryeom, S. W., & Yoon, S. S. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0053 · Cited by 88
RetractedChen, L., Yan, Y., Zhu, L., Cong, X., Li, S., Song, S., Song, H., & Xue, Y. (2017) · Cancer Management and Research · doi:10.2147/cmar.s151026 · Cited by 104
Clinical Importance of Epstein–Barr Virus-Associated Gastric Cancer
Nishikawa, J., Iizasa, H., Yoshiyama, H., Shimokuri, K., Kobayashi, Y. O., Sasaki, S., Nakamura, M., Yanai, H., Sakai, K., Suehiro, Y., et al. (2018) · Cancers · doi:10.3390/cancers10060167 · Cited by 91
Xing, R., Zhou, Y., Yu, J., Yu, Y., Nie, Y., Luo, W., Yang, C., Xiong, T., Wu, W. K. K., Li, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09644-6 · Cited by 91
Evolution and progression of Barrett’s oesophagus to oesophageal cancer
Killcoyne, S., & Fitzgerald, R. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00400-x · Cited by 104
Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects
Hou, W., Zhao, Y., & Zhu, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015321 · Cited by 105
Actionable gene-based classification toward precision medicine in gastric cancer
Ichikawa, H., Nagahashi, M., Shimada, Y., Hanyu, T., Ishikawa, T., Kameyama, H., Kobayashi, T., Sakata, J., Yabusaki, H., Nakagawa, S., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0484-3 · Cited by 92
RHO GTPases in cancer: known facts, open questions, and therapeutic challenges
Bustelo, X. R. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170531 · Cited by 88
Alterations of DNA damage repair in cancer: from mechanisms to applications
Jiang, M., Jia, K., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., He, Y., & Zhou, C. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2920 · Cited by 87
Advances in the management of peritoneal malignancies
Képénékian, V., Bhatt, A., Péron, J., Alyami, M. S., Benzerdjeb, N., Bakrin, N., Falandry, C., Passot, G., Rousset, P., & Gléhen, O. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00675-5 · Cited by 93
Current Trends in Volume and Surgical Outcomes in Gastric Cancer
Marano, L., Verre, L., Carbone, L., Poto, G. E., Fusario, D., Venezia, D. F., Calomino, N., Kaźmierczak-Siedlecka, K., Połom, K., Marrelli, D., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072708 · Cited by 95
“The Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) [9,10] have proposed a molecularbased classification of gastric cancers finding new ways to treat the disease with a more personalized approach.”
BackgroundMolecular classification of gastric cancer
Röcken, C. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1286985 · Cited by 111
PD-1 and PD-L1 blockade in gastrointestinal malignancies
Lote, H., Cafferkey, C., & Chau, I. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.09.004 · Cited by 98
Emerging role of Hippo pathway in gastric and other gastrointestinal cancers
Kang, W., Cheng, A. S. L., Yu, J., & To, K. F. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.1279 · Cited by 91
Helicobacter pylori, Cancer, and the Gastric Microbiota
Wroblewski, L. E., & Peek, R. M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-41388-4_19 · Cited by 95
Proposed Molecular and miRNA Classification of Gastric Cancer
Alessandrini, L., Manchi, M., Re, V. D., Dolcetti, R., & Canzonieri, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061683 · Cited by 98
Shen, Q., Połom, K., Williams, C., de Oliveira, F. M. S., Guergova-Kuras, M., Lisacek, F., Karlsson, N. G., Roviello, F., & Kamali‐Moghaddam, M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.044 · Cited by 92
BMP Signaling in Development, Stem Cells, and Diseases of the Gastrointestinal Tract
Zhang, Y., & Que, J. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034500 · Cited by 91
Landscape of EBV-positive gastric cancer
Saito, M., & Kono, K. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01215-3 · Cited by 100
Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients
Wang, J., Kunzke, T., Prade, V. M., Shen, J., Buck, A., Feuchtinger, A., Haffner, I., Luber, B., Liu, D. H. W., Langer, R., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4383 · Cited by 90
Epigenetic silencing of tumor suppressor genes during in vitro Epstein–Barr virus infection
Saha, A., Jha, H. C., Upadhyay, S. K., & Robertson, E. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503806112 · Cited by 86
Cho, J., Kang, M.-S., & Kim, K.-M. (2016) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2016.16.1.1 · Cited by 87
Lawson, C. D., Fan, C., Mitin, N., Baker, N. M., George, S. D., Graham, D. M., Perou, C. M., Burridge, K., Der, C. J., & Rossman, K. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2923 · Cited by 97
O’Reilly, L. A., Putoczki, T. L., Mielke, L. A., Low, J. T., Lin, A. E.-J., Preaudet, A., Herold, M. J., Yaprianto, K., Tai, L., Kueh, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.003 · Cited by 97
BRAF and AXL oncogenes drive RIPK3 expression loss in cancer
Najafov, A., Zervantonakis, I. K., Mookhtiar, A. K., Greninger, P., March, R. J., Egan, R. K., Luu, H. S., Stover, D. G., Matulonis, U. A., Benes, C. H., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2005756 · Cited by 93
Controversies in the Treatment of Local and Locally Advanced Gastric and Esophageal Cancers
Cohen, D. J., & Leichman, L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7765 · Cited by 88
Robinson, K. M., Crabtree, J., Mattick, J. S. A., Anderson, K. E., & Hotopp, J. C. D. (2017) · Microbiome · doi:10.1186/s40168-016-0224-8 · Cited by 93
Min, A., Kim, J. E., Kim, Y., Lim, J. M., Kim, S., Kim, J. W., Lee, K.-H., Kim, T., Oh, D., Bang, Y., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.037 · Cited by 99
Liu, J.-Y., Peng, C., Yang, X., Huang, C., & Li, Y. (2018) · PubMed Central · Cited by 99
Li, B., Jiang, Y., Li, G., Fisher, G. A., & Li, R. (2020) · JCI Insight · doi:10.1172/jci.insight.136570 · Cited by 94
A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability
Leoni, G., D'Alise, A. M., Cotugno, G., Langone, F., Garzia, I., De Lucia, M., Fichera, I., Vitale, R., Bignone, V., Tucci, F. G., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1072 · Cited by 84
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
Ambrosini, M., Manca, P., Nasca, V., Sciortino, C., Ghelardi, F., Seligmann, J. F., Taïeb, J., & Pietrantonio, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01015-z · Cited by 116
“1), which seem to be enriched in patients with Lynch syndrome 23,33,34 .”
Sarshekeh, A. M., Advani, S., Overman, M. J., Manyam, G., Kee, B. K., Fogelman, D. R., Dasari, A., Raghav, K., Vilar, E., Manuel, S., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173345 · Cited by 84
Epstein–Barr virus: a master epigenetic manipulator
Scott, R. S. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.07.017 · Cited by 92
Hypermutation and microsatellite instability in gastrointestinal cancers
Yuza, K., Nagahashi, M., Watanabe, S., Takabe, K., & Wakai, T. (2017) · Oncotarget · doi:10.18632/oncotarget.22783 · Cited by 86
Humphries, B. A., Wang, Z., Li, Y., Jhan, J.-R., Jiang, Y., & Yang, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3141 · Cited by 92
Cho, S., Yoon, C., Lee, J. H., Chang, K. K., Lin, J.-X., Kim, Y.-H., Kook, M., Aksoy, B. A., Park, D. J., Ashktorab, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1679 · Cited by 85
RetractedKohlruss, M., Grosser, B., Krenauer, M., Slotta‐Huspenina, J., Jesinghaus, M., Blank, S., Novotny, A., Reiche, M., Schmidt, T., Ismani, L., et al. (2019) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.137 · Cited by 90
Phase Separation of Epstein-Barr Virus EBNA2 and Its Coactivator EBNALP Controls Gene Expression
Qiu, P., Wang, L., Qin, Z., Wang, J., Zheng, X., Wei, L., Zhang, X., Zhang, X., Liu, C., Li, Z., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01771-19 · Cited by 87
Gastric Cancer in Young Adults: A Different Clinical Entity from Carcinogenesis to Prognosis
Li, J. (2020) · Gastroenterology Research and Practice · doi:10.1155/2020/9512707 · Cited by 97
“Most patients with GC belong to the genomically stable subtype in the TCGA classification or the microsatellite stable/epithelialmesenchymal transition subtype in the ACRG classification are of young age, and the common genetic aberrations are mutations in CDH1, RhoA, or CLDN18-ARHGAP rearrangements; thus, it is no su…”
BackgroundInflammation and Gastric Cancer
Jaroenlapnopparat, A., Bhatia, K., & Çoban, Ş. (2022) · Diseases · doi:10.3390/diseases10030035 · Cited by 106
“And the last subtype, the genomically stable subtype, involves alteration of CDH1 or RHO family genes [89].”
BackgroundZhou, Y.-J., Li, G., Wang, J., Liu, M., Wang, Z., Song, Y., Zhang, X., & Wang, X. (2023) · Blood Science · doi:10.1097/bs9.0000000000000149 · Cited by 96
Zhao, A., Qian, Y., Sun, H., Hou, X., Pan, J., Liu, X., Zhou, W. J., Chen, Y.-Z., Jiang, X., Li, Z., et al. (2018) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2018.05.003 · Cited by 84
Ko, Y. H. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.109 · Cited by 84
Schlafen 4–expressing myeloid-derived suppressor cells are induced during murine gastric metaplasia
Ding, L., Hayes, M. M., Photenhauer, A. L., Eaton, K. A., Li, Q., Ocádiz-Ruiz, R., & Merchant, J. L. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82529 · Cited by 90
Recent advances in the detection and management of early gastric cancer and its precursors
Waddingham, W., Nieuwenburg, S. A. V., Carlson, S. L., Rodriguez‐Justo, M., Spaander, M. C. W., Kuipers, E. J., Jansen, M., Graham, D. G., & Banks, M. R. (2020) · Frontline Gastroenterology · doi:10.1136/flgastro-2018-101089 · Cited by 95
Robertson, H., Dinkova‐Kostova, A. T., & Hayes, J. D. (2020) · Cancers · doi:10.3390/cancers12123609 · Cited by 104
Bauer, M., Jasinski‐Bergner, S., Mandelboim, O., Wickenhauser, C., & Seliger, B. (2021) · Cancers · doi:10.3390/cancers13205189 · Cited by 92
Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats
Li, J. S. Z., Abbasi, A., Kim, D. H., Lippman, S. M., Alexandrov, L. B., & Cleveland, D. W. (2023) · Nature · doi:10.1038/s41586-023-05923-x · Cited by 86
Deterministic evolution and stringent selection during preneoplasia
Karlsson, K., Przybilla, M. J., Kotler, E., Khan, A., Xu, H., Karagyozova, K., Sockell, A., Wong, W. H., Liu, K., Mah, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06102-8 · Cited by 83
Helicobacter pylori infection and gastric carcinoma
Mégraud, F., Bessède, E., & Varon, C. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.06.004 · Cited by 101
Petrelli, F., Ghidini, M., Barni, S., Steccanella, F., Sgroi, G., Passalacqua, R., & Tomasello, G. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-5832-4 · Cited by 99
A three‐lncRNA expression signature associated with the prognosis of gastric cancer patients
Song, P. K., Jiang, B., Liu, Z., Ding, J., Liu, S., & Guan, W. (2017) · Cancer Medicine · doi:10.1002/cam4.1047 · Cited by 80
Akazawa, Y., Saito, T., Hayashi, T., Yanai, Y., Tsuyama, S., Akaike, K., Suehara, Y., Takahashi, F., Takamochi, K., Ueyama, H., et al. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.04.022 · Cited by 90
Zhang, Y., Yang, L., Kucherlapati, M., Chen, F., Hadjipanayis, A., Pantazi, A., Bristow, C. A., Lee, E. A., Mahadeshwar, H. S., Tang, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.025 · Cited by 82
Tumor immune response and immunotherapy in gastric cancer
Kwak, Y., Seo, A. N., Lee, H. E., & Lee, H. S. (2019) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2019.10.08 · Cited by 92
A comprehensive update on early gastric cancer: defining terms, etiology, and alarming risk factors
Yang, K., Lu, L., Liu, H., Wang, X., Gao, Y., Yang, L., Li, Y., Su, M., Jin, M. L., & Khan, S. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1845140 · Cited by 86
Dna Damage Response Alterations in Gastric Cancer: Knocking down a New Wall
Ricci, A. D., Rizzo, A., & Brandi, G. (2021) · Future Oncology · doi:10.2217/fon-2020-0989 · Cited by 86
Optimized PD-L1 scoring of gastric cancer
Schoemig-Markiefka, B., Eschbach, J., Scheel, A. H., Pamuk, A., Rueschoff, J., Zander, T., Buettner, R., Schroeder, W., Bruns, C. J., Loeser, H., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01195-4 · Cited by 90
Wu, W., Liu, Y., Zeng, S., Han, Y., & Shen, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01166-3 · Cited by 88
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-23
- Volume
- 513
- Issue
- 7517
- Pages
- 202-209
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4170219
- OpenAlex
- W2126547130
- Cited by
- 6,498
- References
- 43
- Citations by year
- 2026: 455 · 2025: 481 · 2024: 569 · 2023: 637 · 2022: 620 · 2021: 737 · 2020: 653 · 2019: 554 · 2018: 560 · 2017: 490 · 2016: 398 · 2015: 297 · 2014: 41
- FWCI
- 327.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- KUMeL Repository (Keimyung University) (submittedVersion, cc-by-nc-nd)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, R01HG007069, U54HG003079, U54HG003273, R01HG005690)
- National Cancer Institute (P30CA16672, K08CA134931, P50CA098258, U24CA143882, P01CA028842, R01CA180006, U24CA143843, U24CA143840, U24CA143858, U24CA126543, U24CA144025, U24CA143866, U24CA143883, U24CA143845, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA143835, K99CA166729, P30CA008748, P30CA016672, P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Keywords
- gastric adenocarcinoma, molecular classification, Epstein-Barr virus, PIK3CA mutation, DNA hypermethylation, PD-L1, PD-L2, microsatellite instability, chromosomal instability, genome stability, RHOA mutations, aneuploidy, targeted therapy, patient stratification
- MeSH terms
- Adenocarcinoma, Herpesvirus 4, Human, Female, Humans, Male, Mutation, Stomach Neoplasms, Genome, Human, Gene Expression Regulation, Neoplastic, Proteome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.